# HLD-0915 (JNJ-101556143)

Source: https://onco.cc/drugs/hld-0915/  
OnCo record `hld-0915` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HLD-0915 (JNJ-101556143) is an experimental oral heterobifunctional small molecule from Halda Therapeutics, in phase 1 trials for metastatic prostate cancer.

## Summary

HLD-0915 (JNJ-101556143) (HLD-0915, JNJ-101556143) is an oral heterobifunctional small molecule (RIPTAC) from Halda Therapeutics, with Johnson & Johnson as acquirer. A once-daily oral therapy built on the RIPTAC platform, which brings a tumour-specific protein together with a protein the cell needs to survive, to kill cancer cells selectively and overcome resistance. Its furthest stage is phase 1, for metastatic prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1/2 NCT06800313 recruiting (sponsor Janssen Research & Development), and an arm in NCT06095089 (Janssen combination study). Johnson & Johnson completed the acquisition of Halda on 29 December 2025. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: HLD-0915; JNJ-101556143
- Tags: pipeline; ctgov-ingest
- Code: HLD-0915
- Modality: Oral heterobifunctional small molecule (RIPTAC)
- Mechanism: A once-daily oral therapy built on the RIPTAC platform, which brings a tumour-specific protein together with a protein the cell needs to survive, to kill cancer cells selectively and overcome resistance.

## Sources

- Halda Therapeutics: medicaldialogues.in: https://medicaldialogues.in/amp/news/industry/pharma/jnj-completes-acquisition-of-halda-therapeutics-its-novel-platform-for-cancer-treatment-161646
- Halda Therapeutics: indianpharmapost.com: https://www.indianpharmapost.com/news/johnson-johnson-completes-305-billion-acquisition-of-halda-therapeutics-18745
- Halda Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06095089
- ClinicalTrials.gov: trials of HLD-0915: https://clinicaltrials.gov/search?intr=HLD-0915

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Halda Therapeutics](https://onco.cc/companies/halda-therapeutics/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- trials: [A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer](https://onco.cc/trials/nct06095089/), [Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer](https://onco.cc/trials/nct06800313/)

---
JSON: https://onco.cc/api/v1/entities/hld-0915.json